[1] Barratt SL, Creamer A, Hayton C, et al.Idiopathic pulmonary fibrosis (IPF): an overview[J]. J Clin Med, 2018, 7(8): 201. [2] 耿艳艳,周植星,胡倩倩,等.特发性肺纤维化治疗靶点及药物研究进展[J].中国新药杂志,2015,24(1):46-51. [3] 中华医学会呼吸病学分会间质性肺疾病学组.特发性肺纤维化诊断和治疗中国专家共识[J].中华结核和呼吸杂志,2016,39(6):427-432. [4] 陈钰清,闫永吉,仇美华,等.吡非尼酮治疗肺纤维化的疗效与安全性 meta分析[J].临床药物治疗杂志,2016,14(4):13-22. [5] Azuma A, Nukiwa T, Tsuboi E, et al.Double-blind,placebocontrolled trail of pirfenidone in patients with idiopathic pulm-onary fibrosis[J]. Am J Respir Crit Care Med, 2005,171(9):1040. [6] Taniguchi H, Ebina M, Kondoh Y, et al.Pirfenidone in idiopathic pulmonary fibrosis[J]. Eur Respir J, 2010, 35(4):821. [7] Noble PW, Albera C, Bradford WZ, et al.CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis( CAPACITY):two randomised trials[J]. Lancet, 2011, 377(9779):1760-1769. [8] 雷凯春,岳红梅,周婷婷.吡非尼酮治疗特发性肺纤维化的临床疗效及不良反应[J].中国新药与临床杂志,2018,37(3):160-163. [9] 李生浩,喻卓.药物性骨骼肌损伤的发生机制[J].医学综述,2015,21(3):406-408. [10] 高千秋,张浩嘉.302 例他汀类药物相关肌肉系统损害的文献分析[J].中国药物警戒,2018,15(8):476-480. |